Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 235 of the 235 references it cites were found in a registry or an index; 53 of the 273 sources its claims cite were checked for support.

The roles of DNA, RNA and histone methylation in ageing and cancer

Open access
Michalak, Ewa M., Burr, Marian L., Bannister, Andrew J., Dawson, Mark A. · 2019 · Nature Reviews Molecular Cell Biology

Abstract

Chromatin is a macromolecular complex predominantly comprising DNA, histone proteins and RNA. The methylation of chromatin components is highly conserved as it helps coordinate the regulation of gene expression, DNA repair and DNA replication. Dynamic changes in chromatin methylation are essential for cell-fate determination and development. Consequently, inherited or acquired mutations in the major factors that regulate the methylation of DNA, RNA and/or histones are commonly observed in developmental disorders, ageing and cancer. This has provided the impetus for the clinical development of epigenetic therapies aimed at resetting the methylation imbalance observed in these disorders. In this Review, we discuss the cellular functions of chromatin methylation and focus on how this fundamental biological process is corrupted in cancer. We discuss methylation-based cancer therapies and provide a perspective on the emerging data from early-phase clinical trial therapies that target regulators of DNA and histone methylation. We also highlight promising therapeutic strategies, including monitoring chromatin methylation for diagnostic purposes and combination epigenetic therapy strategies that may improve immune surveillance in cancer and increase the efficacy of conventional and targeted anticancer drugs.

Overview

CoChat Summary

TL;DR

This review discusses how DNA, RNA and histone methylation are dynamically regulated and dysregulated in ageing and cancer, and how mutations in methylation writers, readers and erasers, oncometabolites and oncohistones contribute to malignancy. It summarizes early clinical trial data for epigenetic therapies targeting DNA and histone methylation and argues that context-dependent biology will require rational combination strategies.

Key findings

  • DNA methylation occurs at around 70% of CpG sites in mammalian genomes, except CpG islands in active promoters; ageing and cancer involve hypomethylation of repetitive elements and hypermethylation at promoter CpGs, polycomb targets and tumour suppressor genes.
  • RNA methylation comprises over 70 known types, but biological functions remain largely unknown; m6A is dynamic and demethylatable, and D2HG inhibits FTO, leading to higher m6A levels in IDH1/2-mutant AML.
  • Age-related clonal haematopoiesis (ARCH) occurs in more than 10% of adults aged 60 years or older; mutations in DNMT3A, TET2 and ASXL1 account for greater than 70% of ARCH cases and are associated with increased haematological malignancy risk and almost twofold increased cardiovascular mortality.
  • Oncohistone H3K27M is found in up to 90% of diffuse intrinsic pontine gliomas, and around 30% of paediatric glioblastomas contain histone gene mutations; in trials, EZH2 inhibitor tazemetostat produced responses in 71% of follicular lymphoma patients with activating EZH2 mutations (11% complete response) versus 33% without EZH2 mutations (31% progressive disease), BAP1-inactivated mesothelioma showed 51% disease control at 12 weeks and 25% sustained to 24 weeks, DOT1L inhibitor pinometostat induced complete remission in 2 of 51 MLL-fusion leukaemia patients, LSD1 inhibitor ORY-1001 gave partial responses in 3 of 14 AML patients, and azacytidine response rates reached up to 60% in MDS.

Methods

  • Design: narrative review; no primary experimental data are reported.
  • Data/sample: published literature and early-phase clinical trial data on DNA, RNA and histone methylation in ageing and cancer, including a table of selected clinical trials.
  • Main analysis: synthesis of methylation mechanisms, cancer-associated mutations and therapeutic strategies; no systematic review or meta-analysis is described.

Limitations

  • Stated: preclinical models have significant limitations; genetically engineered mouse models fail to recapitulate intratumour heterogeneity, and patient-derived xenografts have major limitations in clonal representation and lack an effective immune system.
  • Stated: preclinical evaluation of epigenetic compounds has not equated well with clinical success; many drugs showed remarkable preclinical promise but modest clinical efficacy, and mechanisms of resistance and the significance of non-histone substrates are not fully elucidated.
  • Evident: as a narrative review, it lacks systematic search, quality assessment or meta-analysis and does not report primary data; conclusions rely on cited literature and selected trials.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41580-019-0143-1

Cites

235 of 235 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

16 Valid · 19 Not valid · 120 Not checked · 48 Own results and interpretations

104 more claims · 23 with their cited sources checked

Create a free account to see all 203 claims and to verify the 220 references still open.

See all claims — free account
  • Probably not a substantial claim. 29
  • It may state two separate claims as one. 73
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 235 references

Research works printed but not linked: 3

  1. Zaccara, S., Ries, R. J. & Jaffrey, S. R. Reading, writing and erasing mRNA methylation. Nat. Rev. Mol. Cell Biol. In the press.
  2. Xhemalce, B., Dawson, M. A. & Bannister, A. J. in Epigenetic Regulation and Epigenomics (ed. Meyers, R. A.) 657–703 (Wiley-Blackwell, Weinheim, 2012).
  3. Biggar, K. K. & Li, S. S. C. Non-histone protein methylation as a regulator of cellular signalling and function. Nat. Rev. Mol. Cell Biol. 16, 5 (2014). · DOI · Paper page

Cited by

See all 586

Metadata

Authors
Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A.
Affiliations
  • The University of Melbourne (AU)
  • University of Cambridge (GB)
Corresponding author
  • Bannister, Andrew J.
  • Dawson, Mark A.
Venue
Nature Reviews Molecular Cell Biology
Published
2019-07-03
Volume
20
Issue
10
Pages
573-589
ISSN
  • 1471-0072 (ISSN-L)
  • 1471-0080
OpenAlex
W2955248709
Cited by
549
References
235
Citations by year
2026: 36 · 2025: 62 · 2024: 104 · 2023: 83 · 2022: 92 · 2021: 78 · 2020: 83 · 2019: 10
FWCI
5.81
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Reviews Molecular Cell Biology (publishedVersion)
  • PubMed (publishedVersion)
  • Apollo (University of Cambridge) (submittedVersion)
  • Apollo
Funders
Cancer Research UK (17001, 20097)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer-related gene regulation
Keywords
chromatin methylation, DNA methylation, histone methylation, RNA methylation, aging, cancer, epigenetic therapy, DNA repair, gene expression regulation, tumor surveillance, clinical trials, cancer diagnosis
MeSH terms
DNA, Neoplasm, Histones, Neoplasm Proteins, Neoplasms, RNA Processing, Post-Transcriptional, RNA, Neoplasm, DNA Methylation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The roles of DNA, RNA and histone methylation in ageing and cancer. https://app.cochat.ai/papers/10.1038/s41580-019-0143-1
The paper
Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019). The roles of DNA, RNA and histone methylation in ageing and cancer. Nature Reviews Molecular Cell Biology. https://doi.org/10.1038/s41580-019-0143-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.